

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort

Tongai G Maponga¹, Anna L McNaughton², Marije Van Schalkwyk³, Susan Hugo³,
Chikezie Nwankwo⁴, Jantjie Taljaard³, Jolynne Mokaya², David A Smith²,
Cloete van Vuuren⁵, Dominique Goedhals⁶, Shiraz Gabriel⁴, Monique I Andersson^{1,7},
Wolfgang Preiser¹, Christo van Rensburg⁴, Philippa C Matthews^{2,7,8}

¹ Division of Medical Virology, Stellenbosch University / National Health Laboratory Service Tygerberg, Cape Town, South Africa

² Nuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road, Oxford, UK

³ Division of Infectious Diseases, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa

⁴ Division of Gastroenterology, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa

⁵ Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa

⁶ Division of Virology, Universitas Academic Laboratories, National Health Laboratory Service/University of the Free State, Bloemfontein, South Africa

⁷ Department of Microbiology and Infectious Diseases, Oxford University Hospitals, John Radcliffe Hospital, Headington, Oxford, UK

⁸ NIHR British Research Council, John Radcliffe Hospital, Headington, Oxford, UK

* Corresponding author: philippa.matthews@ndm.ox.ac.uk

Keywords: hepatitis B virus, HBV, HIV, treatment, elimination, viral load, tenofovir, dolutegravir, hepatocellular carcinoma, South Africa, coinfection, sustainable development goals

34 **ABSTRACT**

35

36 **Objective:** Prompted by international targets for elimination of hepatitis B virus (HBV)
37 infection, we performed a cross-sectional observational study of adults with chronic HBV
38 (CHB) infection in South Africa, characterising individuals with HBV monoinfection vs. those
39 coinfecting with HBV/HIV, to evaluate the impact of therapy and to guide improvements in
40 clinical care as guidelines for antiviral therapy change over time.

41 **Design:** We prospectively recruited 112 adults with CHB, of whom 38 (34%) had HIV
42 coinfection, over one year in a university hospital in Cape Town, South Africa. We recorded
43 cross-sectional demographic, clinical and laboratory data.

44 **Results:** Adults with HBV monoinfection were comparable to those with HBV/HIV coinfection
45 in terms of age, sex and body mass. HBeAg-positive status was more common among those
46 with coinfection ($p=0.01$). Compared to HBV/HIV coinfection, HBV monoinfected patients were
47 less likely to be on antiviral treatment and less likely to have been assessed by fibroscan
48 ($p<0.0001$ in each case); they were also more likely to have detectable HBV viraemia
49 ($p=0.01$), moderate/severe thrombocytopaenia ($p=0.007$), elevated bilirubin ($p=0.002$), and
50 APRI score >2 ($p=0.02$), suggesting underlying liver disease. Three cases of hepatocellular
51 carcinoma were reported, all in patients with HBV monoinfection.

52 **Conclusion:** Individuals with HBV monoinfection are disadvantaged in terms of clinical
53 assessment and appropriate antiviral therapy compared to those with HIV coinfection,
54 associated with relatively worse liver health. Enhanced advocacy, education, resources and
55 infrastructure are required to optimise interventions for CHB.

56

57

58 **‘SUMMARY BOX’**

59 ***What is already known about this subject?***

60 Chronic infection with hepatitis B virus (HBV) is the cause of a substantial burden of disease in
61 sub-Saharan Africa, with morbidity comparable to that caused by tuberculosis or malaria.
62 Rates of liver disease associated with HBV are rising, but international sustainable
63 development goals have set ambitious targets for elimination of the infection as a public health
64 threat by the year 2030. In many parts of southern Africa, HBV is co-endemic with HIV
65 infection. The conventional paradigm has been that the coinfection is associated with worse
66 outcomes from both infections. However, this accelerated pathology may be halted by the
67 introduction of antiviral therapy, with tenofovir being central to regimens for both HIV and HBV
68 infection. This agent suppresses viral replication, leading to improved outcomes in both HIV
69 and HBV infection, but certain questions remain to be considered, including its role in
70 coinfection, the risk of drug resistance and toxicity, and the impact of changing antiretroviral
71 regimens over time.

72

73 ***What are the new findings?***

74 We have studied adults with CHB under review at a teaching hospital in South Africa,
75 reviewing clinical and laboratory data in the presence and absence of HIV coinfection. The
76 group with coinfection was statistically more likely to be HBeAg-positive, suggesting an
77 increased risk of accelerated liver disease. However, we show that the HBV monoinfected
78 group are in fact disadvantaged: they are less likely to be on antiviral therapy (even when
79 meeting treatment criteria), and therefore less likely to be virologically suppressed.
80 Furthermore, coinfecting patients are less likely to undergo full clinical evaluation and are
81 characterised by increased rates of liver disease based on a range of markers including
82 platelet count, bilirubin and fibrosis scores. We found no evidence of nephrotoxicity in
83 association with the use of tenofovir. Thus, overall we show that the HBV monoinfected group
84 have worse liver outcomes in comparison to those with HBV/HIV coinfection. Those with HIV
85 coinfection have a therapeutic advantage, as a result of secure access to monitoring and
86 consistent provision of antiviral therapy, and there is no evidence of a risk of toxicity
87 associated with treatment.

88

89 ***How might it impact on clinical practice in the foreseeable future?***

90 Those with HBV monoinfection are vulnerable to evolving complications. We highlight the
91 importance of careful clinical surveillance of this group, the importance of early diagnosis and

92 investigation, and a low threshold for the introduction of antiviral therapy. As antiretroviral
93 therapy regimens change over time, with a move towards dolutegravir-based dual therapy,
94 there is a risk of HBV/HIV-infected patients losing access to tenofovir therapy. Our results
95 highlight the importance of maintaining tenofovir provision and scaling up treatment at a
96 population level in order to make progress towards 2030 elimination targets.

97

98 INTRODUCTION

99 The burden of chronic infection with hepatitis B virus (HBV) in southern Africa is high, and in this
100 setting the distribution overlaps with populations in which HIV infection is endemic [1]. Due to
101 high rates of coinfection, and the overlap in antiviral regimens, there is a pressing need to
102 develop an enhanced understanding of the interplay between these infections, and to capitalise
103 on opportunities for deploying existing HIV infrastructure to improve HBV diagnosis, clinical care
104 and prevention. International sustainable development goals set a target for elimination of HBV
105 as a public health problem by the year 2030 [2]. Developing insights into the characteristics and
106 outcomes of chronic HBV (CHB) mono-infection and HBV/HIV coinfection will underpin improved
107 strategies for monitoring, prognostication, patient stratification and therapy. Changes in
108 recommendations for cART regimens for HIV infection should consider the individual and public
109 health impact of therapy on individuals who are co-infected with HBV, particularly in the co-
110 endemic populations of sub-Saharan Africa.

111
112 A traditional paradigm suggests that individuals with HBV/HIV coinfection might have a worse
113 prognosis from chronic liver disease than those with HBV mono-infection, typically linked with
114 higher rates of HBeAg-positivity and higher viral loads [1,3], lower CD4+ T cell counts,
115 increased incidence of liver fibrosis [4] and hepatocellular carcinoma (HCC), higher rates of
116 vertical HBV transmission, and higher overall mortality [5]. However, this picture is not
117 consistent between populations (even within individual studies [6]) and the interplay between
118 viruses may be affected by specific characteristics of the host or viral population [7], and by
119 changes in treatment guidelines over time.

120
121 Lamivudine (3TC) and tenofovir (most commonly in the form of tenofovir disoproxil fumarate,
122 TDF) have established track records of safety and tolerability in both HIV and HBV infection.
123 Long-term 3TC use is hampered by a high rate of selection of resistance [8], while TDF is
124 favoured as the genetic barrier to resistance is high [9]. Following publication of the START trial
125 in 2015, HIV treatment is now initiated irrespective of clinical or immunological status [10]. This
126 practice is now enshrined in '90-90-90' targets, seeking to have 90% of cases diagnosed, 90%
127 of these on treatment, and 90% of these virologically suppressed [11]. TDF is one of the
128 recommended choices for the NRTI backbone of cART for HIV [12]; in South Africa, TDF is
129 used for first-line cART in combination with 3TC/EFV or FTC/EFV [13]. In second-line regimens,
130 TDF is commonly added to a protease inhibitor (PI) with a backbone of zidovudine (AZT)+3TC.

131 Thus the majority of HIV-positive individuals with HBV coinfection receive TDF as a component
132 of routine first or second-line therapy.

133
134 In contrast, for HBV monoinfection, TDF is prescribed only for a subset of patients, based on
135 algorithms that incorporate assessment of the patient (age and sex), virologic status (HBV DNA
136 viral load) and the presence of underlying fibrotic or inflammatory liver disease (ALT,
137 elastography score, ultrasound appearance, biopsy results) [14–16]. WHO targets for 2030 aim
138 for 90% of HBV cases to be diagnosed, and for 80% of those eligible for treatment to be
139 receiving it [17]. However, only a small minority of those living with CHB are currently aware of
140 their status [18], patient stratification and monitoring using laboratory and radiological
141 approaches is not accessible in many settings [18], and current assessment misses a high
142 proportion of patients who should be treated [19].

143
144 Recognising the need for improved characterisation of HBV infection, both alone and in
145 combination with HIV coinfection, we have undertaken a cross-sectional analysis of adults with
146 CHB in an urban cohort in South Africa. We set out to explore the differences between
147 individuals with monoinfection and coinfection, and to compare rates and outcomes of antiviral
148 therapy, with the aim of informing current and future therapeutic guidelines.

149

150 **METHODS**

151 ***Clinical cohort***

152 We recruited adults with CHB infection, with or without HIV coinfection, attending routine clinical
153 follow-up in hepatology and infectious diseases outpatient clinics at Tygerberg Hospital, a
154 tertiary referral hospital in Cape Town. HIV clinics within the referral area are encouraged to
155 send all patients diagnosed with HIV-HBV coinfection to the Tygerberg clinic for counselling and
156 baseline investigations including clinical assessment, laboratory tests and elastography.
157 Patients are followed at the clinic at intervals according to the baseline findings.

158
159 Cases were defined as being HBsAg-positive (typically over a period of >6 months of clinical
160 follow up) and were recruited into a cross-sectional cohort (Oxford-South Africa Hepatitis
161 Cohort, 'OxSA-Hep'), commencing July 2018. We here present the results of a planned interim
162 analysis of data after 12 months of recruitment.

163

164 We recorded treatment with antiviral therapy at the time of recruitment to the study, routine
165 clinical laboratory data (including serological markers of HBV infection, creatinine, liver function
166 tests and platelet count), and documented elastography scores when the patient had been
167 assessed by fibroscan. We recorded data in a LabKey database [20] using a unique
168 pseudonymised patient ID number.

169

170 ***Generation and analysis of laboratory data***

171 Biochemical and serological data were generated on the Cobas 6000 series e601 module
172 analyzer (Roche Diagnostics GmbH, Germany). Platelet counts were obtained using the Advia
173 2120i analyzer (Siemens Healthcare Diagnostics Inc, USA). HIV and HBV viral loads were
174 measured using Cobas Ampliprep/Taqman tests (Roche Molecular Diagnostics, the
175 Netherlands).

176

177 The upper limit of normal (ULN) for ALT was 19 iu/ml for females and 30 iu/ml for males [16,21],
178 ULN for AST = 40 iu/ml, ULN for BR = 17 mmol/L. We calculated liver fibrosis scores, AST to
179 Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) as follows:

- 180 • $APRI = (AST / ULN\ AST) / (Platelet\ count \times 100)$
- 181 • $FIB-4 = (Age\ in\ years \times AST) / (Platelet\ count \times \sqrt{AST})$

182 We used thresholds of FIB-4 >3.25 (97% specificity, and positive predictive value of 65% for
183 advanced liver fibrosis [22]), and APRI >2 (91% specific for cirrhosis [23,24]).

184

185 We measured renal function based on estimated glomerular filtration rate (eGFR) as follows:

- 186 • $186 \times (creatinine\ (\mu mol/L) / 88.4)^{-1.154} \times (age\ in\ years)^{-0.203} \times (0.742\ if\ female) \times (1.210\ if$
187 $black) [25].$

188 Normal renal function is defined as $eGFR \geq 90\ ml/min/1.73m^2$. We grouped together individuals
189 with renal impairment, defined as chronic kidney disease (CKD) Stage II (eGFR 60-89 ml/min)
190 or Stage III (eGFR 30-59 ml/min). We defined moderate/severe thrombocytopaenia as a platelet
191 count $< 75 \times 10^3/\mu l$ [26].

192

193 ***Elastography***

194 Elastography to quantify liver stiffness (an assessment of inflammation and/or fibrosis) is not
195 undertaken consistently in this setting, but is performed in a subset of patients at the discretion
196 of the clinical team using the Fibroscan 402 (Echosens, Paris, France). Elastography scores are

197 not reliable in individuals with a high body mass index or during pregnancy, and would not be
198 undertaken in these circumstances. Due to the cross-sectional nature of the cohort, we
199 recorded elastography scores at a single time point only.

200

201 ***Treatment indications and outcomes***

202 We have referred to HBV treatment recommendations published by the UK National Institute for
203 Clinical Excellence (NICE) [21], the European Association for the Study of the Liver (EASL) [15],
204 and South African national guidelines [16]. All concur in advising tenofovir or entecavir as first-
205 line options, and recommend that stratification for therapy should be based on laboratory
206 parameters, on the presence and extent of existing liver disease assessed by imaging and/or
207 biopsy, and on consideration of other individual clinical and demographic factors.

208

209 Due to resource constraints, liver biopsy is rarely undertaken in this setting and we have
210 primarily used laboratory parameters to assess treatment eligibility. South African guidelines
211 suggest consideration of therapy for individuals who are HBeAg-positive with HBV DNA
212 >20,000 IU/ml and ALT above ULN, or who are HBeAg-negative with HBV DNA >2,000 IU/ml
213 and ALT above ULN, with the aim of achieving durable suppression of HBV DNA to low or
214 undetectable levels and normalisation of ALT [16]. Individuals with HIV coinfection are routinely
215 treated with first line combined antiretroviral therapy (cART) that includes HBV-active agents
216 [13]. In practice in this setting, TDF is therefore first line therapy for CHB, both in the presence
217 and absence of HIV infection.

218

219 ***Statistical analysis***

220 We analysed data using GraphPad prism v 8.0.1. For continuous variables, we used Mann
221 Whitney Test; for categorical variables we used Fisher's Exact Test. Linear regression was used
222 to assess associations between two continuous variables. For multivariate analysis, we
223 performed multivariate logistic regression using bayesglm function of the R package.

224

225 ***Ethics***

226 Ethics approval was provided by University of Oxford Tropical Research Ethics Committee (ref.
227 OXTREC 01-18) and Stellenbosch University Human Research Ethics Committee (HREC ref.
228 N17/01/013). All participants provided written valid informed consent. A STROBE statement to
229 support the quality of this observational study is available (Suppl. Table 1)

230

231 ***Patient and Public Involvement***

232 Our teams run an active program of public engagement, with events taking place throughout the
233 year in the UK and in South Africa. We have recently redesigned patient information sheets
234 based on feedback from the clinics at recruitment sites, to improve clarity and accessibility of
235 communication [27].

236

237 **RESULTS**

238 ***Representation of HBV monoinfection and HIV/HBV coinfection in an adult cohort***

239 We recruited 112 adults with HBV infection (55% male), representing 74 adults with HBV
240 monoinfection (66%) and 38 with HBV/HIV coinfection (34%) (Fig 1). The full metadata are
241 available in Suppl. Table 2. Summary data for the cohort are presented in Table 1, showing a
242 comparison of attributes of HBV monoinfection and HBV/HIV coinfection. Extended material are
243 presented in Suppl. Table 3. Based on small numbers and borderline statistical significance at
244 univariate level, we did not anticipate multivariate analysis to demonstrate many significant
245 variables, but those that were significant are referenced in the footnotes to Tables 1 and 2.

246

247 The majority of participants were of South African origin (88%; Suppl. Fig 1). There was no
248 significant difference in sex, age or body weight between the monoinfected and coinfecting
249 groups ($p=0.24$, 0.28 , and 0.20 respectively; Table 1). HBeAg-positive status was significantly
250 more common among individuals with HIV coinfection (34%) compared to HBV monoinfected
251 individuals (12%); $p=0.009$; Fig 2A; Table 1.

252

253 ***Antiviral therapy and virologic outcomes in HBV monoinfection vs HIV/HBV coinfection***

254 Antiviral therapy and outcomes are shown in Fig 1 and Table 2. As anticipated, based on HIV
255 treatment guidelines [13], a significantly greater proportion of the coinfecting group was on
256 antiviral therapy compared to the monoinfected group (97% vs. 49% respectively, $p<0.0001$; Fig
257 2B; also significant on multivariate analysis). Accordingly, HBV DNA was more likely to be
258 suppressed below the limit of detection in coinfecting than monoinfected patients (57% vs 33%,
259 respectively; $p=0.03$; Fig 2C), and absolute values for HBV DNA viral load (VL) were also
260 significantly lower in the coinfecting group than the monoinfected ($p=0.049$; Suppl Fig 2A).
261 Duration of antiviral therapy was recorded for 29 individuals with HBV monoinfection (median 29
262 months) and 27 individuals with HIV coinfection (median 37 months); $p=0.1$.

263

264 In the HBV/HIV coinfecting group, 37/38 adults were on antiviral therapy that included HBV-
265 active agents (TDF and/or 3TC); one patient was not on therapy. HIV VL data were available for
266 33/37, being undetectable in 21/33 (64%) and <1000 RNA copies/ml in 5/33 (15%). Overall,
267 suppression of HIV viraemia was associated with suppression of HBV viraemia ($p=0.02$; Fig 2D,
268 Suppl Fig 2B). However, among individuals with undetectable HIV VL, HBV DNA was still
269 detectable in 5/21 (24%). Among these, one was being treated with 3TC as the only HBV-active
270 agent, with HBV DNA VL 1.0×10^5 IU/ml. Suppression of HIV viraemia suggests adherence to
271 cART, and the high HBV viral load is therefore consistent with 3TC resistance. The other four
272 were receiving TDF-based combination therapy, making drug resistance a less likely
273 explanation for HBV viraemia (HBV VL 20-5444 IU/ml). Treatment start date was ≥ 15 months
274 prior to the date of recruitment (recorded in 3/5 cases), making it unlikely that HBV viraemia was
275 detectable because therapy had only recently been instituted.

276

277 ***Proportion of untreated HBV monoinfected patients who meet treatment criteria***

278 We reviewed the data for 36 HBV monoinfected individuals off therapy to determine the
279 proportion of these who met treatment criteria. Using South African guidelines [16], 6/36 (17%)
280 were treatment eligible (3/36 HBeAg-positive with HBV DNA >20,000 IU/ml plus 5/36 HBeAg-
281 negative with HBV DNA >2,000 IU/ml, of whom 6/8 had ALT >ULN). Based on the European
282 guidelines, 7/36 (19%) individuals would be eligible for therapy (HBV DNA >2,000 IU/ml and
283 ALT >ULN) [15].

284

285 ***Prevalence of liver disease: laboratory data***

286 We assessed laboratory data and elastography scores as markers for underlying liver disease.
287 There was no significant difference in ALT or AST between monoinfected vs. coinfecting
288 individuals (Suppl. Table 3). For BR, the proportion with an elevated value was higher in the
289 monoinfected than in the coinfecting group (albeit not reaching statistical significance, $p=0.08$;
290 Fig 3A), but the absolute values were significantly higher in those with monoinfection ($p=0.003$;
291 Fig 3C). Thrombocytopenia can be an indicator of chronic liver disease as a result of a variety
292 of mechanisms, including splenic sequestration and myelosuppression [26]. Strikingly, all the
293 individuals with moderate/severe thrombocytopenia were in the HBV monoinfected group (Fig
294 3B,D) suggesting a subgroup of individuals with established liver disease. We calculated fibrosis

295 scores from laboratory data, finding a higher proportion of the HBV monoinfected group had
296 scores predictive of cirrhosis/fibrosis (for APRI: $p=0.02$, Fig 4A; for FIB-4: $p=0.1$, Fig 4B).
297 Despite no difference in median APRI or FIB-4 between monoinfected and coinfecting groups, it
298 is striking that 12/14 individuals with elevated fibrosis scores were in the HBV monoinfected
299 group (Fig 4C, 4D).

300

301 ***Prevalence of liver disease: elastography and clinical data***

302 Only a small proportion of the cohort had elastography data ($n=38/112$, 34%). Individuals with
303 HBV/HIV coinfection were more likely to be assessed by elastography, undertaken in 30/38
304 cases (79%) compared to only 8/74 (11%) of individuals with HBV monoinfection ($p<0.0001$;
305 Table 1; also significant on multivariate analysis). Among 38 individuals with elastography data,
306 there were slightly higher scores in the HBV monoinfected group compared to those with
307 coinfection, although this did not reach statistical significance (median score 6.9 kPa vs 5.6 kPa,
308 respectively; $p=0.3$; Table 1).

309

310 A greater proportion of the HBV monoinfected group had fibroscan scores that would meet
311 criteria for treatment. A threshold of 6 kPa [21], was exceeded in 4/8 (50%) of monoinfected
312 patients vs. 12/30 (40%) of coinfecting patients; while the stringent threshold of 9kPa [15] was
313 exceeded in 3/8 (38%) of monoinfected patients vs 4/30 (13%) coinfecting patients. However,
314 due to small numbers in each group, neither of these differences reached statistical significance
315 ($p=0.7$ and $p=0.1$, respectively).

316

317 We reviewed clinical records for complications reported by specialist doctors in 106 cases.
318 Among these, 18/106 (17%) had documented complications of HBV infection, including 17
319 cases of cirrhosis (16% prevalence) and 3 cases of HCC (3% prevalence); two patients had
320 both cirrhosis and HCC. All HCC cases occurred in the context of HBV monoinfection. The
321 prevalence of hepatic complications was almost twice as high in HBV monoinfection (14/68;
322 21%) compared to HBV/HIV coinfection (4/38; 11%), although this difference did not reach
323 statistical significance due to small numbers in each group ($p=0.3$; Table 1).

324

325 ***Evidence of renal dysfunction***

326 Chronic kidney disease (CKD) can arise in association with HIV infection, and is also a potential
327 side effect of TDF therapy [28]. Therefore, we examined this cohort for the presence of CKD
328 based on calculation of eGFR, available for 99 individuals. CKD stage II or III was present in

329 31/99 (31%) of the cohort. However, we found no difference in rates of CKD between individuals
330 with HBV monoinfection vs HBV/HIV coinfection (CKD II/III present in 21/63 (33%) vs 10/36
331 (28%), respectively, $p=0.7$). There was no evidence of nephrotoxicity among those on TDF;
332 indeed there was a trend towards increased prevalence of CKD among the untreated group vs
333 those on antiviral treatment (CKD II/III present in 18/63 (29%) vs 13/32 (41%) respectively;
334 $p=0.2$).

335

336 **DISCUSSION**

337 ***Context and primary conclusions***

338 Developing a detailed understanding of the characteristics of CHB, and the clinical interplay with
339 coendemic HIV, is important to drive forward improvements in care provision, with gains to be
340 made both for individuals populations. Although successful vaccination campaigns are well
341 established, modelling studies predict long timeframes to elimination [29,30], and programmes
342 to enhance diagnosis and treatment will therefore be crucial in the decade ahead.

343

344 The traditional paradigm suggests that patients with HBV/HIV coinfection may have worse
345 outcomes than those with HBV monoinfection, and we confirmed a significantly higher
346 prevalence of HBeAg-positive status in those with HIV coinfection. Despite this, our data
347 indicate that the monoinfected group is disadvantaged compared to those with coinfection,
348 evidenced by the significant association between monoinfection and lower rates of access to
349 appropriate clinical surveillance, lower rates of antiviral treatment (even among those who meet
350 treatment criteria), higher HBV viral loads, more established liver disease (hyperbilirubinaemia,
351 thrombocytopaenia and elevated fibrosis scores), and an increased risk of clinical
352 complications. A previous report from the same setting also documents elevated rates of severe
353 fibrosis in HBV monoinfected compared to their HBV/HIV coinfecting counterparts [31], although
354 this observation is not consistent as another African study found elevated APRI scores in
355 patients with coinfection [4].

356

357 In our cohort, there was no difference in the prevalence of elevated hepatic transaminases (ALT
358 and AST) between monoinfected and coinfecting patient groups. It is important to observe that
359 significant evidence of progressive liver disease can be present even in the absence of
360 abnormalities in conventional 'liver function tests'. This highlights a need for clinical surveillance
361 that is broader than any single serum marker.

362

363 The worse overall outcomes among the population with HBV monoinfection may stem from the
364 sustained neglect of HBV infection as a clinical and public health problem [18], relatively
365 complex algorithms for HBV treatment stratification, and less consistent and rigorous access to
366 tenofovir monotherapy [32]. HCC can arise independent of liver fibrosis [16], and therefore even
367 among HBV-infected individuals with no objective evidence of inflammatory or fibrotic liver
368 disease, there is a potential for the emergence of malignancy. Our data raise the hypothesis
369 that adults with HBV monoinfection may be coming to clinical care too late, underlining a
370 pressing need for simplified, scalable approaches to HBV diagnosis as well as treatment [33].

371
372 ***HBV suppression on therapy***
373 Despite the immunological defect associated with HIV infection and the higher prevalence of
374 HBeAg+ status in this group, HBV viraemia can be successfully suppressed in the majority of
375 coinfecting patients using conventional TDF-based cART regimens. However, even on
376 appropriate antiviral therapy, over a quarter of patients still had detectable HBV viraemia. This
377 may be explained by sub-optimal adherence to therapy, pharmacokinetics (drug absorption,
378 levels within liver tissue), or drug resistance, and the long timeframes over which HBV viraemia
379 may decline on therapy [34]. Careful clinical surveillance is therefore important even in the
380 context of treatment, while there is a need for further studies to investigate TDF resistance [8].

381
382 ***Changes to cART regimens with influence on HBV therapy***
383 Changes to cART recommendations are developing, based on the success of dual therapy with
384 dolutegravir (DTG) regimens, both in the context of prior viraemic suppression [35] and for
385 salvage after failure of first-line treatment [36,37]. DTG/3TC is a common combination, but other
386 regimens do not contain any HBV active agents, (e.g. DTG combined with rilpivirine (RPV) [38],
387 emtricitabine (FTC) [39], or ritonavir-boosted lopinavir (LPVr) [37]). These regimens have not
388 yet been robustly evaluated in African populations, and are deemed inappropriate in the context
389 of HBV coinfection [40], although there are data demonstrating the efficacy of TDF/FTC in
390 mediating HBV suppression [41]. As dual therapy combinations enter clinical practice in Africa,
391 enhanced awareness and scrutiny will be critical to ensure that HBV-positive individuals are
392 diagnosed and treated with appropriate HBV-active agents, and that there is caution regarding
393 the potential for selection of HBV drug resistance on DTG/3TC treatment.

394
395 ***Drug resistance***

396 We identified a patient with phenotypic evidence of 3TC-resistant HBV in our cohort, congruent
397 with evidence for the consistent selection of resistance among individuals on 3TC monotherapy
398 [42], and in keeping with another African study that documented a high prevalence of 3TC
399 resistance among coinfecting patients [4]. Tenofovir resistance is less well substantiated, and
400 can be difficult to confirm phenotypically due to the slow rate of HBV DNA suppression after
401 institution of therapy [26]; however, there are reports confirming the potential for resistance to
402 this agent (as previously reviewed [8]).

403

404 ***Caveats and limitations***

405 We have studied a small cohort, representing a distinct geographical setting and focusing on
406 clinical care delivery within the specific environment of a tertiary care university hospital, which
407 benefits from enhanced resource and infrastructure compared to many other healthcare
408 settings. Even in this setting, missing data are problematic. Assessment with elastography is not
409 consistently deployed, and serological markers are expensive, and not routinely undertaken at
410 each clinic visit. Our small cohort may be underpowered to identify true associations, as
411 reflected by borderline statistical significance of some of the relationships that we observe.

412

413 On the one hand, our study may be biased by the likelihood that patients with more advanced
414 pathology are most likely to be diagnosed and referred for tertiary-level follow-up; this could lead
415 to us over-estimating liver disease in those with HBV mono-infection. On the other hand, outside
416 this specific setting, the majority of cases of HBV mono-infection are undiagnosed, and those
417 with a diagnosis are less likely to be under routine surveillance, less likely to be stratified for
418 treatment, and less likely to receive a regular supply of appropriate therapy supported by clinical
419 monitoring; on these grounds, our cohort significantly under-represents the true burden of liver
420 disease. However, irrespective of the magnitude of the effect, head-to-head comparison of
421 comparable mono-infected and coinfecting groups within this setting consistently suggest a
422 treatment advantage in the coinfecting group, and a risk of continued emergence of liver
423 pathology among those with HBV mono-infection.

424

425 We have used platelet count as a marker of liver disease, but this is a non-specific approach, as
426 thrombocytopenia has diverse potential causes. The sensitivity and specificity of APRI and
427 FIB-4 varies between settings, and further evaluation is specifically required in African
428 populations [43]. We were unable to apply other fibrosis scores, such as gamma-

429 glutamyltranspeptidase-to-platelet ratio (GPR) [43,44], as the extended panel of liver function
430 tests required is not routinely collected.

431
432 We have taken a cross-sectional view, from which long-term outcomes can only be extrapolated
433 with caution. We have not been able to capture data regarding important influences on HBV and
434 HIV viral loads, including compliance with treatment and the presence of antiviral resistance.
435 HBV genotype data are not available for this cohort, but are known to have a role in disease
436 progression, and may add future insights [7,45].

437
438 **Conclusions**

439 High standards of provision of HIV services, with consistent access to diagnosis, surveillance
440 and tenofovir-based treatment, are advantageous in delivering a high standard of clinical care
441 for those with HBV coinfection. The majority of HBV monoinfected patients remain undiagnosed,
442 but - even among those who know their status and are under follow-up - there remains a gap in
443 care provision, rendering them susceptible to long-term liver complications. In order to make
444 progress towards 2030 elimination goals, service providers should capitalise on the existing
445 infrastructure and investment deployed for HIV as both a precedent and a foundation for
446 improved clinical care for HBV infection.

447
448

449 **FUNDING**

450 PCM and the OXSAHEP cohort are funded by Wellcome (grant ref 110110).

451

452 **ACKNOWLEDGEMENTS**

453 We are grateful to the clinic and laboratory staff in infectious diseases, virology and
454 gastroenterology at Tygerberg Hospital, Cape Town, and to the patients for their participation in
455 this study.

456

457 **CONFLICTS OF INTEREST**

458 Nil to declare

459

460

461 **FIGURE LEGENDS**

462

463 **Figure 1: Summary of cohort of 112 adults with HBV infection from Cape Town, South**
464 **Africa, showing numbers with HBV mono-infection and HIV/HBV coinfection, those**
465 **receiving therapy and those with suppressed viraemia.** Viral load data were not available in
466 21 cases, of whom 13 were HBV mono-infected and 8 were HBV/HIV co-infected (shown in
467 dashed lines and box). Green boxes indicate number with suppressed viraemia, yellow indicate
468 number with one virus suppressed and the other detectable, red indicate number with no
469 viraemic suppression.

470

471 **Figure 2: Characteristics of adults with CHB, based on HBeAg status, HBV therapy and**
472 **virologic outcomes of therapy, comparing those with HBV mono-infection vs HBV/HIV**
473 **coinfection from a cross-sectional study in Cape Town, South Africa.** A: Proportion of each
474 group testing HBeAg-positive. B: Proportion of mono-infected vs co-infected adults receiving
475 antiviral therapy; C: Proportion of mono-infected vs co-infected adults with HBV suppressed
476 below the limits of detection (<20 IU/ml) on antiviral therapy. D: HBV/HIV co-infected individuals
477 only, showing proportion who have suppressed HIV and/or HBV viral load on antiviral therapy.
478 In all cases, p-values calculated by Fisher's Exact Test, and the number of individuals
479 represented in each group is shown in brackets below the columns.

480

481 **Figure 3: Assessment of liver disease in adults with HBV mono-infection vs HBV/HIV**
482 **coinfection in a cross-sectional study in Cape Town, South Africa based on serum**
483 **bilirubin and platelet count.** BR - serum bilirubin; Plt - platelet count. Panels A and B: p-values
484 by Fisher's Exact Test comparing the number in each group falling above and below specified
485 thresholds (BR>17 mmol/L; moderate/severe thrombocytopenia defined as $plt < 75 \times 10^3/\mu l$).
486 Number in each group indicated in brackets under the columns; this varies according to data
487 availability. Panels C and D: p-values by Mann Whitney test; bars indicate median and IQR. C:
488 serum bilirubin levels are significantly elevated in the group with HBV mono-infection. D:
489 Distribution of plt highlights all of those with moderate/severe thrombocytopenia (below dashed
490 line) are in HBV mono-infected group.

491

492 **Figure 4: Assessment of liver disease using fibrosis scores derived from laboratory data**
493 **in adults with HBV mono-infection vs HBV/HIV coinfection in a cross-sectional study of**
494 **adults in Cape Town, South Africa.** APRI - AST to Platelet Ratio Index; FIB-4 - Fibrosis-4
495 score (for formulae, see methods). Number in each group indicated in brackets under the
496 columns; this varies according to data availability. Panels A and B: p-values by Fisher's Exact
497 Test comparing the number in each group falling above and below the threshold for
498 cirrhosis/fibrosis (APRI >2; FIB-4 >3.25). Panels C and D: p-values by Mann Whitney test and
499 bars indicate median and IQR. No significant difference in median value for either score, but the
500 scatter plots show that individuals with scores above the threshold are predominantly in the
501 mono-infected group.

502

503

504 **Table 1: Summary of clinical and laboratory parameters recorded from a cohort of 112**
 505 **adults with HBV infection in Cape Town, South Africa, comparing groups with HBV**
 506 **mono-infection (n=74) versus HIV/HBV coinfection (n=38).** For extended version of table, see
 507 Suppl data table 3.

	Whole Cohort	HBV mono-infection	HIV/HBV coinfection	p-value ^a
Sex M:F (% male)	62:50 (55%)	44:30 (59%)	18:20 (47%)	0.24
Median age in years at enrollment ^b (IQR)	44 (36-53)	46 (36-55)	41 (37-50)	0.28
Median body weight in kg ^c (IQR)	73 (60-85)	75 (60-87)	72 (59-80)	0.20
Proportion HBeAg positive ^d (%)	20/102 (19.6%)	8/67 (11.9%)	12/35 (34.3%)	0.009
Proportion with elevated ALT above ULN ^e (%)	49/109 (45%)	33/72 (46%)	16/37 (43%)	0.84
Proportion with elevated AST above ULN ^f (%)	27/85 (32%)	16/50 (32%)	11/35	1.0
Median BR ^g , mmol/L (IQR)	7 (5-13)	9 (5-15)	5 (4-9)	0.003
Proportion with elevated BR above ULN ^g (%)	14/95 (14.7%)	12/61 (19.7%)	2/34 (6.0%)	0.08
Median platelet count ^h , x10 ³ / ul (IQR)	226 (158-292)	227 (153-291)	249 (166-307)	0.38
Proportion with thrombocytopenia ^h (%)	10/97 (10.3%)	10/62 (16%)	0/35 (0%)	0.01
Proportion with APRI score >2	8/79 (10%)	8/47 (17%)	0/32 (0%)	0.02
Proportion with FIB-4 score >3.25	12/78 (15%)	10/46 (22%)	2/32 (6%)	0.11
Proportion assessed by elastography (%)	38/112 (34%)	8/74 (11%)	30/38 (79%)	<0.0001*
Proportion with elastography score >9kPa (%)	7/38 (18%)	3/8 (38%)	4/30 (13%)	0.14

508 IQR = inter-quartile range; ALT = alanine transferase; ULN = upper limit of normal. ^ap-value for categorical variables
 509 by Fisher's Exact Test, and for continuous variables by Mann Whitney test. ^bAge available for 111/112 individuals.
 510 ^cBody weight available for 108/112 individuals. ^dHBeAg status available for 102/112 individuals. ^eALT available for
 511 60/62 males and 49/50 females, with ULN defined as 19 iu/ml for females and 30 iu/ml for males. ^fAST available for
 512 85/112 individuals, with ULN defined as 40 iu/ml. ^gBR available for 95/112 individuals; ULN defined as 17 mmol/L.
 513

514 ^hPlatelet count available for 97/112 individuals; moderate/severe thrombocytopenia defined as platelet count <75
 515 $\times 10^3$ / ul [26]. ⁱCKD (chronic kidney disease) stages II and III defined as eGFR <90 ml/min/1.73m². ^jClinical
 516 complications reviewed for 108/112 individuals, defined as a documented diagnosis of HCC and/or cirrhosis.
 517 ^kElastography data available for 38/112 individuals. * Also significant by multivariate analysis.
 518

519 **Table 2: Summary of antiviral therapy treatment and outcomes from a cohort of 112**
 520 **adults with HBV infection in Cape Town, South Africa, comparing features of those with**
 521 **HBV mono-infection (n=74) versus HIV/HBV coinfection (n=38).**

	Whole Cohort	HBV mono-infection	HIV/HBV coinfection	p-value ^a
Proportion on antiviral treatment ^b (%)	71/108 (66%)	34/70 (49%)	37/38 (97)	<0.0001*
Median duration of therapy ^c , months (IQR)	31 (14-66)	29 (7-63)	37 (18-66)	0.1
Median HBV DNA viral load IU/ml ^d (range)	31 (0-1.7 $\times 10^8$)	90 (0 - 1.7 $\times 10^8$)	0 (0-1.0 $\times 10^8$)	0.049
Proportion of HBV viraemia undetectable ^e	40/96 (42%)	20/61 (33%)	20/35 (57%)	0.03

522
 523 ^ap-value for categorical variables by Fisher's Exact Test, and for continuous variables by Mann Whitney test.
 524 ^bAntiviral treatment data available for 108/112 individuals. ^cDuration of therapy defined for 29 HBV mono-infected and
 525 27 HBV/HIV coinfecting individuals. ^dHBV DNA viral load available for 61/74 HBV mono-infected and 35/38 HIV
 526 coinfecting individuals. ^eUndetectable HBV DNA defined as viral load in serum below limit of detection of assay
 527 (typically HBV DNA <20 IU/ml). * Also significant by multivariate analysis.
 528
 529
 530
 531

532 **SUPPLEMENTARY MATERIAL:**

533

534 **Suppl table 1: STROBE statement** (STrengthening the Reporting of OBServational studies in
535 Epidemiology) to support the quality of this observational cross-sectional study.

536

537 **Suppl table 2: Raw data collected for 112 adults with chronic hepatitis B virus infection**
538 **recruited into a cross-sectional cohort in Cape Town, South Africa.** These data are
539 available on-line: <https://figshare.com/s/756eff7c317ef041cf0e>. This link will be converted to a
540 permanent open access DOI ([10.6084/m9.figshare.9649400](https://doi.org/10.6084/m9.figshare.9649400)) on acceptance of the paper for
541 publication.

542

543 **Suppl table 3: Summary of parameters recorded from a cohort of 112 adults with HBV**
544 **infection in Cape Town, South Africa, comparing features of those with HBV**
545 **monoinfection (n=74) versus HIV/HBV coinfection (n=38).** This is an extended version of
546 tables 1 and 2 presented in the main text.

547

548 **Suppl Fig 1: Ethnic origins (birth country) of participants enrolled into a cross-sectional**
549 **cohort of HBV infection in Cape Town, South Africa.**

550

551 **Suppl Fig 2: Plasma viral loads for HBV and HIV in a cross-sectional study of adults in**
552 **Cape Town, South Africa.** (A) Distribution of HBV DNA viral load in individuals with HBV
553 monoinfection and HBV/HIV coinfection; horizontal lines indicate median with whiskers
554 representing IQR; the numbers shown in brackets under each category report the number of
555 individuals represented; p-values by Mann Whitney U test. (B) Relationship between HIV viral
556 load and HBV viral load in serum, with R^2 and p values by linear regression based on \log_{10} viral
557 load; note the point where HIV and HBV VL=0 represents 18 individuals.

558

559 REFERENCES

- 560 1. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV
561 coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. *J Clin Virol*.
562 2014;61: 20–33.
- 563 2. Griggs D, Stafford-Smith M, Gaffney O, Rockstrom J, Ohman MC, Shyamsundar P, et al.
564 Policy: Sustainable development goals for people and planet. *Nature*. 2013;495: 305–307.
- 565 3. van Griensven J, Phirum L, Choun K, Thai S, De Weggheleire A, Lynen L. Hepatitis B and
566 C co-infection among HIV-infected adults while on antiretroviral treatment: long-term
567 survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia. *PLoS One*.
568 2014;9: e88552.
- 569 4. Ndow G, Gore ML, Shimakawa Y, Suso P, Jatta A, Tamba S, et al. Hepatitis B testing and
570 treatment in HIV patients in The Gambia-Compliance with international guidelines and
571 clinical outcomes. *PLoS One*. 2017;12: e0179025.
- 572 5. Christian B, Fabian E, Macha I, Mpangala S, Thio CL, Ulena N, et al. Hepatitis B virus
573 coinfection is associated with high early mortality in HIV-infected Tanzanians on
574 antiretroviral therapy. *AIDS*. 2019;33: 465–473.
- 575 6. Matthews PC, Beloukas A, Malik A, Carlson JM, Jooste P, Ogwu A, et al. Prevalence and
576 Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South
577 Africa and Botswana. *PLoS One*. 2015;10: e0134037.
- 578 7. McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, et al. Insights
579 From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.
580 *Gastroenterology*. 2018; doi:10.1053/j.gastro.2018.07.058
- 581 8. Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti A-M, Goedhals D, et al. A
582 systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A
583 call for urgent action. *PLoS Negl Trop Dis*. 2018;12: e0006629.
- 584 9. Park E-S, Lee AR, Kim DH, Lee J-H, Yoo J-J, Ahn SH, et al. Identification of a quadruple
585 mutation that confers tenofovir resistance in chronic hepatitis B patients. *J Hepatol*.
586 2019;70: 1093–1102.


- 587 10. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et
588 al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med.*
589 2015;373: 795–807.
- 590 11. 90-90-90: treatment for all [Internet]. [cited 7 Aug 2019]. Available:
591 <https://www.unaids.org/en/resources/909090>
- 592 12. HIV/AIDS Treatment Guidelines. In: AIDSinfo [Internet]. [cited 7 Aug 2019]. Available:
593 <https://aidsinfo.nih.gov/guidelines>
- 594 13. Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, et al. Adult
595 antiretroviral therapy guidelines 2017. *South Afr J HIV Med.* 2017;18: 776.
- 596 14. Overview | Hepatitis B (chronic): diagnosis and management | Guidance | NICE. Available:
597 <http://nice.org.uk/guidance/cg165>
- 598 15. European Association for the Study of the Liver. Electronic address:
599 easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017
600 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol.*
601 2017;67: 370–398.
- 602 16. Spearman CWN, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C, et
603 al. South African guideline for the management of chronic hepatitis B: 2013. *S Afr Med J.*
604 2013;103: 337–349.
- 605 17. Organization WH, Others. Combating hepatitis B and C to reach elimination by 2030:
606 advocacy brief [Internet]. World Health Organization; 2016. Available:
607 https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf
- 608 18. O’Hara GA, McNaughton AL, Maponga T, Jooste P, Ocamo P, Chilengi R, et al. Hepatitis B
609 virus infection as a neglected tropical disease. *PLoS Negl Trop Dis.* 2017;11: e0005842.
- 610 19. Abera H, Desalegn H, Berhe N, Mekasha B, Medhin G, Gundersen SG, et al. The WHO
611 guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in
612 Ethiopia. *J Hepatol.* 2019;70: 1065–1071.
- 613 20. Data Management and Workflow Software for Research - LabKey. In: LabKey [Internet].
614 [cited 22 Aug 2019]. Available: <https://www.labkey.com/>

- 615 21. Nice Clinical Guideline, Hepatitis B (chronic): diagnosis and management [Internet]. NICE
616 Clinical Guideline; 2013.
- 617 22. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a
618 simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
619 [Internet]. *Hepatology*. 2006. pp. 1317–1325. doi:10.1002/hep.21178
- 620 23. Lin Z-H, Xin Y-N, Dong Q-J, Wang Q, Jiang X-J, Zhan S-H, et al. Performance of the
621 aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related
622 fibrosis: An updated meta-analysis [Internet]. *Hepatology*. 2011. pp. 726–736.
623 doi:10.1002/hep.24105
- 624 24. Chou R, Wasson N. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic
625 Hepatitis C Virus Infection [Internet]. *Annals of Internal Medicine*. 2013. p. 807.
626 doi:10.7326/0003-4819-158-11-201306040-00005
- 627 25. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using
628 standardized serum creatinine values in the modification of diet in renal disease study
629 equation for estimating glomerular filtration rate. *Ann Intern Med*. 2006;145: 247–254.
- 630 26. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al.
631 Thrombocytopenia associated with chronic liver disease. *J Hepatol*. 2008;48: 1000–1007.
- 632 27. Matthews P, Maponga T, Mofokeng M, Goedhals D. Hepatitis B virus (HBV) patient
633 information leaflet [Internet]. 2019. doi:10.6084/m9.figshare.8969654.v1
- 634 28. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. *Hepatology*.
635 2009;49: S185–95.
- 636 29. McNaughton AL, Lourenço J, Hattingh L, Adland E, Daniels S, Van Zyl A, et al. HBV
637 vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical
638 cohort and dynamic model. *BMC Med*. 2019;17: 43.
- 639 30. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for
640 global elimination of hepatitis B: a modelling study. *Lancet Infect Dis*. 2016;16: 1399–1408.
- 641 31. Maponga TG, Andersson MI, van Rensburg CJ, Arends JE, Taljaard J, Preiser W, et al.
642 HBV and HIV viral load but not microbial translocation or immune activation are associated


- 643 with liver fibrosis among patients in South Africa. *BMC Infect Dis.* 2018;18: 214.
- 644 32. Maponga TG, Nwankwo C, Matthews PC. Sustainable Development Goals for HBV
645 elimination in South Africa: challenges, progress, and the road ahead. *South African*
646 *Gastroenterology Review.* 2019;17: 15–25.
- 647 33. Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al.
648 Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology
649 Commission. *Lancet Gastroenterol Hepatol.* 2019;4: 135–184.
- 650 34. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of
651 HBV by tenofovir in HBV/HIV coinfecting patients: a systematic review and meta-analysis.
652 *PLoS One.* 2013;8: e68152.
- 653 35. Baldin G, Ciccullo A, Borghetti A, Di Giambenedetto S. Virological efficacy of dual therapy
654 with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-
655 term data from clinical practice. *J Antimicrob Chemother.* 2019; doi:10.1093/jac/dkz009
- 656 36. Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, et al.
657 Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage
658 regimens in HIV-1 infected, highly treatment-experienced subjects. *HIV Clin Trials.*
659 2018;19: 242–248.
- 660 37. Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, et al. Dolutegravir
661 versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor
662 therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an
663 open-label, non-inferiority, phase 3b trial. *Lancet Infect Dis.* 2019;19: 253–264.
- 664 38. Casado JL, Monsalvo M, Fontecha M, Vizcarra P, Rodriguez MA, Vivancos MJ, et al.
665 Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected
666 patients in a clinical setting. *HIV Res Clin Pract.* 2019;20: 64–72.
- 667 39. Diaco ND, Strickler C, Giezendanner S, Wirz SA, Tarr PE. Systematic De-escalation of
668 Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus
669 Emtricitabine or Lamivudine in Swiss HIV-positive Persons. *EClinicalMedicine.* 2018;6: 21–
670 25.
- 671 40. Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-

- 672 1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. *Expert*
673 *Opin Pharmacother.* 2018;19: 713–738.
- 674 41. Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, et al. Patterns
675 and causes of suboptimal response to tenofovir-based therapy in individuals coinfectd with
676 HIV and hepatitis B virus. *Clin Infect Dis.* 2013;56: e87–94.
- 677 42. Gu L, Han Y, Li Y, Zhu T, Song X, Huang Y, et al. Emergence of Lamivudine-Resistant
678 HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfectd with HIV
679 and HBV in China. *PLoS One.* 2015;10: e0134539.
- 680 43. O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, et al. Liver
681 function tests and fibrosis scores in a rural population in Africa: estimation of the burden of
682 disease and associated risk factors [Internet]. *Gastroenterology.* medRxiv; 2019.
683 doi:10.1101/19000968
- 684 44. Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gamma-
685 glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis
686 in patients with chronic HBV infection in West Africa. *Gut.* 2016;65: 1369–1376.
- 687 45. Kramvis A. Molecular characteristics and clinical relevance of African genotypes and
688 subgenotypes of hepatitis B virus. *S Afr Med J.* 2018;108: 17–21.
- 689


A HBeAg status




B On anti-viral therapy



C HBV suppressed on therapy




D HIV & HBV suppressed on therapy




BR

A




Plt


B




C



D



APRI



FIB-4

